Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

Front Pharmacol. 2024 Oct 25:15:1497520. doi: 10.3389/fphar.2024.1497520. eCollection 2024.

Authors

Cataldo Martucci¹, Andrew Dennis Allen¹, Nadia Moretto¹, Valentina Bagnacani¹, Alessandro Fioni¹, Riccardo Patacchini¹, Maurizio Civelli¹, Gino Villetti¹, Fabrizio Facchinetti¹

Affiliation

¹ Corporate Pre-Clinical R&D, Chiesi Farmaceutici S.p.A., Parma, Italy.

Abstract

[This corrects the article DOI: 10.3389/fphar.2024.1343941.].

Keywords: P38 alpha; chronic obstructive pulmonary disease; cytokines; inflammation; neutrophilia.

Copyright © 2024 Martucci, Allen, Moretto, Bagnacani, Fioni, Patacchini, Civelli, Villetti and Facchinetti.

Publication types

Published Erratum